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Abstract Breast cancer affects approximately 12 % women
worldwide and results in 14 % of all cancer-related fatalities.
Breast cancer is commonly categorized into one of four main
subtypes (luminal A, luminal B, human epidermal growth
factor receptor 2 (HER2) positive and basal), indicating mo-
lecular characteristics and informing treatment regimes. The
most severe form of breast cancer is metastasis, when the
tumour spreads from the breast tissue to other parts of the
body. Significantly, the primary tumour subtype affects rates
and sites of metastasis. Currently, up to 5 % of patients present
with incurable metastasis, with an additional 10–15 % of pa-
tients going on to develop metastasis within 3 years of diag-
nosis. MicroRNAs (miRNAs) are short 21–25 long nucleo-
tides that have been shown to significantly affect gene expres-
sion. Currently, >2000 miRNAs have been identified and sig-
nificantly, specific miRNAs have been found associated with
diseases states. Importantly, miRNAs are found circulating in
the blood, presenting an opportunity to use these circulating
disease-related miRNAs as biomarkers. Clearly, the identifi-
cation of circulating miRNA specific to metastatic breast can-
cer presents a unique opportunity for early disease identifica-
tion and for monitoring disease burden. Currently however,
few groups have identified miRNA associated with metastatic
breast cancer. Here, we review the literature surrounding the
identification of metastatic miRNA in breast cancer patients,
highlighting key areas where miRNA biomarker discovery
could be beneficial, identifying key concepts, recognizing crit-
ical areas requiring further research and discussing potential
problems.
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1 Introduction
Breast cancer is the second most common cancer diagnosed
worldwide, affecting approximately one in eight women dur-
ing their lifetime [1]. It affects 1.3 million women each year
and accounts for 23 % of all cancer cases and 14 % (465,000)
of all cancer-related deaths [2]. The most severe form of breast
cancer occurs when the cancer spreads from the breast tissue
to other regions of the body (metastasis), significantly increas-
ing the tumour burden and often resulting in a fatal diagnosis.
Breast cancer metastasis follows a cascade starting with local
invasion of the surrounding tissue, spreading into the blood or
lymphatic vessels and ending with dissemination of tumour
cells to distal organs [3, 4] (Fig. 1, left). Despite modern treat-
ments, metastatic breast cancer (MBC) is often incurable, with
up to 5 % of patients presenting with distal metastases at time
of diagnosis [2]. Currently, distal metastasis (M1) occurs in
10–15 % of patients within the first 3 years. Furthermore,
approximately one third of women who have breast cancer
with no lymph node involvement at time of diagnosis will
develop distal metastases [5]. Significantly, the rate and site
of metastasis can vary largely and is thought to be dependent
on primary tumour subtype. Clearly, further knowledge is
needed to both diagnose and treat metastatic breast cancer.
Recently, microRNAs (miRNAs) have shown promise as
new biomarkers for many cancers, including metastatic breast
cancer [6–8]. Importantly, miRNAs have been linked to all
stages along the metastatic cascade in breast cancer [9–15]
(Fig. 1, right). Here we examine studies using circulating
miRNAs as biomarkers for metastases, markers for tumour
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recurrence and response to clinical treatments. We likewise
discuss the potential applications of miRNA for therapeutic
metastatic breast cancer diagnosis, treatment and basic
research.
2 MicroRNA
MicroRNAs (or miRNAs) were originally discovered in the
early nineties in Caenorhabditis Elegans [16]. MicroRNAs are
a 21–25 long class of small non-protein coding RNA that
function as gene regulators by inhibiting the degradation of
their target mRNAs and inhibiting translation (Fig. 2).
miRNAs have been demonstrated to be involved in cell de-
velopment, differentiation, proliferation and apoptosis [16].
The first human, disease-related miRNA characterized was
from chronic lymphocytic leukemia [17] and subsequently,
circulating miRNA were identified in patients with diffuse
large B-cell lymphoma [18]. Consequently, miRNAs were
linked tomany other diseases and cancers [19, 20]. Since then,
>2000 miRNAs have been identified in humans and these
miRNAs regulate an estimated 30 % of all human genes
[21]. miRNA can exert their action in cancers through both
tumour suppression and oncogenic mechanisms (as oncomirs)
[16, 22]. Fragile sites and genomic regions involved in onco-
genic rearrangements in cancer are similarly thought to
Fig. 1 Stages of breast cancer
metastasis. Left: Order of process
resulting in breast cancer
metastasis. Right: Circulating
miRNA associated with key steps
in the metastatic cascade
Fig. 2 miRNA biogenesis and mechanism of action
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influence the production of cancer-related miRNA [23]. Fur-
thermore, as a proof-of-principle for any potential therapeutic
application of miRNA, circulating miRNAs have been identi-
fied which correlate with breast cancer subtypes (Table 1)
[24–27].
2.1 miRNA biogenesis and action
miRNAs are formed from precursors called pri-miRNAs that
are processed in the nucleus by Drosha, an RNA III type
nuclease. These pri-miRNAs are transported to the cytoplasm
by exportin-5, where they are cleaved by Dicer, another RN-
Ase II I enzyme, forming an asymmetr ic duplex
(miRNA:miRNA). This miRNA duplex is then separated,
and the mature target miRNA molecule is incorporated into
the RNA-induced silenced complex (RISC) where it binds a
member of the Argonaute (Ago) protein family [the other
miRNA molecule (miRNA*) is normally degraded] [16, 28,
29]. The active RISC complex is then able to target mRNA
transcripts with a sequence complementary to the mature in-
corporated miRNA molecule, leading to inhibition of protein
expression (Fig. 2). miRNA can be exported from cells pack-
aged in membrane-bound extracellular compartments
(exosomes) or bound to RNA binding proteins [30].
Exosomes provide another method of extracellular signalling
as they are able to bind and merge with other cells, thus
influencing their environment. Furthermore, exosomes have
been directly implicated in cancer [31]. Significantly,
miRNAs are differentially secreted or selectively packaged
into exosomes, with different cell and tumour types displaying
distinctive miRNA profiles [32].
2.2 Breast cancer diagnosis
Currently, breast cancer can be subcategorized based on the
status (+/−) of the hormone receptors oestrogen receptor (ER)
and progesterone receptor (PR) and the Receptor tyrosine-
protein kinase erbB-2 (ERBB2 or HER2). Furthermore, recent
genetic testing has enabled the molecular subtyping of breast
cancers [33, 34]. Presently, there are four major molecular
subtypes: luminal A, ~50–60 % of breast cancers; luminal
B, 10–20 %; HER2+ve, 15–20 %, with the remaining 10–
20 % considered Basal subtype [35]. Further subcategorizing
the common molecular breast cancer subtypes has allowed
clinicians to tailor treatments to each individual
patients cancer [36]. In particular, the Oncotype DX test eval-
uates 16 cancer-related genes and 5 reference genes, with the
results used to estimate the likely reoccurrence in patients and
diagnostically to determine if a patient should receive chemo-
therapy [37]. Significantly, as miRNAs have been implicated
in cancer metastasis, miRNA signatures are being pursued as
novel clinical diagnostic targets to allow further subtyping of
breast cancer and for predicting metastasis or therapeutic re-
sistance [38–41]. The potential of miRNA as biomarker tar-
gets is facilitated by their stability in blood and their
ability to withstand repeated freezing and thawing cy-
cles [42].
2.3 miRNA in metastatic breast cancer tissue
Identifying and categorizing miRNAs expressed during the
different stages of metastases will accelerate any therapeutic
potential of these biomarkers, while illuminating the underly-
ing mechanisms of cancer [43]. Currently, a number of studies
have investigatedmiRNA expression profiles (upregulation or
downregulation) of metastatic breast cancer tissue, providing
insights into the processes of breast cancer initiation, progres-
sion and maintenance [44–47]. Significantly, it has been dem-
onstrated that restoring the expression of individual miRNA
observed to be lost in breast cancer models (such as miR-31,
miR-126 or miR-335) can suppress metastasizes in vivo [48,
49]. Additionally, it has been suggested that cancer stem cells
may influence metastasis [50–52], which would further con-
tribute to any breast cancer miRNA profile. It is hoped that
identifying breast cancer-specific miRNA and their functional
relevance will lead to improvements in the early detection and
treatment of tumours, particularly in younger patients.
2.4 Metastases
Breast cancer metastasises though the lymphatic system or via
the circulatory system and is the overwhelming cause of mor-
tality in patients with malignancies, causing 90 % of deaths in
solid tumours [53].Metastasis in breast cancer is characterized
by a distinctive spread via regional lymph nodes to the lungs,
liver, brain and bones [54]. Importantly, the rates and sites of
distal metastasis can vary depending on age and stage of di-
agnosis [55, 56]. The most common site of metastases is the
bone, often the first site of distal metastases in up to 50 % of
patients [57], with lungs and liver as the second and third most
common metastatic sites (respectively) (Fig. 3a, left). Signif-
icantly, 10–15 % of metastatic breast cancer patients will de-
velop brain metastases, making breast cancer the second most
common source of brainmetastasis [58]. A similar distribution









Luminal A + + − miR-29a, miR-181a, miR-
652
[24]
Luminal B + + + miR-342 [25]
HER2+ve + − + miR-10b, miR-21 [26]
Basal (TNBC) − − − miR-210 [27]
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of metastasis is seen following relapse (post-treatment), with
~22 % of patients having multiple sites of metastasis (Fig. 3b,
right) [59, 60].
Further examining metastasis by molecular breast cancer
subtypes, distinctive patterns of metastasis sites are observed
(Table 2). Bone metastases remain the most common metasta-
tic site in luminal A, B and HER2+ve breast cancers [59, 61,
62]. However, basal cancers were found to primarily metasta-
size to the lungs [63]. Interestingly, luminal cancers also tend
to have a lower rate of brain metastases. Significantly, brain
metastasis for the HER2+ve subtype is high [64], despite the
implementation of trastuzumab-based treatments for HER2+
ve breast cancers in the late 1990s. As Herceptin is not expect-
ed to cross the blood brain barrier, it is not believed to have
influenced these rates. Currently, a number of circulating
miRNA have been identified that are dysregulated (up or
down regulated) in breast cancer metastasis (Fig. 3c). Identi-
fying circulating miRNA associated with distinct metastatic
sites could provide another powerful diagnostic tool for clini-
cians to evaluate disease stage and monitor progression.
2.5 Subtype and metastasis stage
Currently, the severity of a person’s breast cancer is based on
the TNM staging, where T describes the tumour size, N de-
fines the lymph node status (+/−) and M relates to any distant
metastases (0/1). In addition to TNM staging, breast cancer
can be also divided into groups, stages I–V, depending on size
and metastatic spread. Significantly, this combined staging is
used clinically to inform the choice of treatment regime. How-
ever, TNM staging has its limitations and drawbacks, includ-
ing overtesting and uncertainties in staging due to limits in
sampling auxiliary lymph nodes. Furthermore, the four breast
cancer molecular subtypes contain different disease progres-
sion, survival and relapse rates. Luminal subtypes tending to
have slower metastatic spread, lower reoccurrence rates and
better outcomes than HER2+ve or basal subtypes [61,
65–69]. This difference is independent of histological subtype
or time of detection, with the majority of basal carcinomas
detected in the early stages of breast cancer. When comparing
median survival (from time of first distal metastasis), luminal
A and B subtypes display longer overall survival (2.2 and
1.6 years) compared to HER2+ve subtype (1.3 years). How-
ever, the basal subtype has the worst overall survival rate
(0.7 years). This is reflected in the presentation rates of the
metastatic disease, stratified by molecular subtype (Table 3).
Significantly, the relapse rates vary considerably by sub-
type, with HER2+ve the highest (51.4 %), followed by lumi-
nal B (42.9 %), basal (35.1 %) and luminal A (27.8 %). Inter-
estingly, in addition to the lowest recurrence rate, luminal A
relapse also occurs later than the other subtypes [61]. Clini-
cally, HER2+ve cancers have a poor prognosis; however,
following development of anti-HER2 treatments, there has
been an improvement in disease-free survival (from 72.2 to
78.6 %) [70, 71]. Bone remains the most common primary
metastatic site, while luminal B has a higher rate of metastases
to other visceral organs (such as liver), compared to luminal
Fig. 3 a Sites of metastatic breast cancer at presentation/diagnosis. b
Recurrence sites of metastatic breast cancer. c Summary of published
miRNA-associated breast cancer
Table 2 Sites of breast cancer metastasis by molecular subtypes
Metastasis sites Breast cancer subtype
Luminal A Luminal B HER2+ve Basal
Brain 6.6 % 8.2 % 23.3 % 18.1 %
Lungs 25.1 % 29.2 % 32.4 % 35.4 %
Bone 62.1 % 64.5 % 47.7 % 32.2 %
Liver 25.1 % 26 % 39.9 % 23.8 %









Luminal A 2–2.6 27.8 2.2
Luminal B 1–2.5 42.9 1.6
HER2 5–6 51.4 1.3
Basal 4–5 35.1 0.7
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A. The basal subtype often presents with a younger onset,
larger mean tumour size and higher grade, with the lowest
overall survival [72, 73].
MicroRNAs have the potential to provide an additional
mechanism for classifying breast cancer subtypes and tracking
disease progression. A number of studies have investigated
microRNAs in tissue as a means for identifying the main
molecular breast cancer subtypes [24–26, 74–76]. Important-
ly, recent studies have found that microRNAs (miR-210, miR-
328, miR-484 and miR-874) have the potential to predict
prognosis or risk of recurrence [26, 77, 78]. Furthermore, it
has been shown that microRNAs may be able to identify a
subtype-specific response to treatment [27, 79, 80].
2.6 Breast cancer treatments
Currently, surgery is the primary treatment for early stage
breast cancer. However, the use of chemotherapy, radiothera-
py and hormone therapy has vastly improved survival rates
[81–83]. For the treatment of metastatic breast cancer, chemo-
therapy and radiotherapy are used in the neoadjuvant setting,
before breast conservative surgery or mastectomy and axillary
node clearance. In progressive disease (stage IV), chemother-
apy and radiotherapy are the principal treatments, along with
hormone therapy. Defining metastatic specific miRNA has the
potential to categorize breast cancer and inform and improve
treatment choices. Furthermore, the use of specific miRNA as
therapeutics has the potential to one day become a valid treat-
ment option [84–86]. Indeed, there are current clinical trials
investigating the efficacy of using miRNA to treat cancer [87].
2.7 Chemotherapy and miRNA
Chemotherapy usually involves a combination of drugs and is
the leading treatment, often combined with hormone therapy,
in metastatic breast cancer. The most common chemothera-
peutics used are anthracyclines (doxorubicin and epirubicin),
taxanes (paclitaxel and docetaxel), fluorouracil (5-FU) and
cyclophosphamide. Currently, there is no evidence of benefit
of one regime over another. However, a meta-analysis has
indicated a benefit of adding taxanes to an anthracycline-
based regime, demonstrating a 5 year risk reduction of 5 %
in disease-free survival and 3 % in overall survival [88]. Sig-
nificantly, HER2+ve patients treated with trastuzumab in
combination with chemotherapy had increasedmedian surviv-
al rates from 20.3 to 25.1 months [89]. Despite these treatment
advancements, a large proportion of patients do not respond to
traditional chemotherapy or hormone therapy [90]. In this
context, circulating miRNAs have been explored as potential
biomarkers, to predict treatment response [91–96]. Currently,
only a few recent studies have explored the relationship of
miRNAs with subtype-specific treatment [94, 97, 98]
(Table 4). The early identification of circulating miRNA that
can diagnose disease and/or chemotherapeutic responses will
greatly facilitate improved treatments, leading to better out-
comes for patients.
3 Diagnosing metastatic disease
Mammography is the gold standard for breast cancer screen-
ing, but it is mainly used for detection of local disease and is
unreliable for diagnosing metastatic disease, with a false pos-
itive rate of ~50 % (7–9 % of these patients require a biopsy)
[99]. Sentinel lymph nodes are the first lymph node in a tu-
mour bed that receives lymphatic drainage from the tumour
tissues, and sentinel lymph node biopsy (SLNB) currently
provides the most accurate diagnosis for metastatic disease
[100]. Currently, SLNB is recommended for early breast can-
cer, without any clinical evidence of nodal involvement [101].
However, SLNB only diagnoses regional metastasis. If distal
metastases are suspected, SLNB needs to be combined with
additional techniques, such as imaging. The development of
an accurate biomarker, such as circulating miRNA, to diag-
nose or predict metastatic spread, could negate/reduce the
need for many patients to undergo invasive procedures or
surgery.
3.1 Circulating miRNA as biomarkers in metastatic breast
cancer
Identifying circulating miRNA to use as biomarkers for met-
astatic breast cancer is currently a key priority for many re-
search groups (Table 5). The first miRNA shown to be highly
expressed in metastatic breast cancer was miR-10b (using
mouse and human cells), with a clinical correlation in primary
breast carcinomas [111]. A subsequent study confirmed this,
finding elevated miR-10b, miR-34a and miR-155 levels in
patients with metastatic breast cancer [7]. Further supporting
this, it was recently shown that miR-10b and miR-373 were
increased in lymph node positive breast cancer [108]. Excit-
ingly, a significant increase in circulating miR-10b and miR-
373 was demonstrated in lymph node positive patients, com-
pared to patients with no nodal involvement or healthy con-
trols. Differences in miRNA levels in lymph node positive
patients were also observed in a subsequent study [106],
where higher levels of miR-20a and miR-214 were found in
lymph node positive patients, compared to lymph node nega-
tive patients. miR-210 was also identified as a potential mark-
er for lymph node metastasis, however only in a small cohort
[94]. Interestingly, miR-10b was identified as a potential bio-
marker for brain [109] and bone [110] metastases in breast
cancer. Together however, these independent results cast
doubt on the use of miR-10b as a metastatic specific marker.
Furthermore, miR-299-5p and miR-411 were found to have
significant differences in metastatic breast cancer patients,
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with the additional miRs miR-215 and miR-452 of interest,
without reaching statistical significance [105]. Additionally,
miR-21 has also been identified as a marker for breast cancer
and predictor of stage [103]. Recently, eight miRNAs (miR-
141, miR-200a, miR-200b, miR-200c, miR-203, miR-210,
miR-375 and miR-801) were found to be significantly higher
in patients with circulating tumour cells (CTC) [104]. In an-
other study, higher levels of miR-105 were found in early
onset breast cancers that metastasized, compared to cancer
that did not [102]. This study also found that overexpression
of miR-105 promoted metastasis in vivo. The miRNAs miR-
17 and miR-155 have been identified as potential
differentiators between metastatic and non-metastatic breast
cancer [107]. Supporting those studies, a number of these
miRNAs have previously been identified as markers in meta-
static triple negative breast cancer samples [79]. As the above
publications did not specifically state the sites of metastases,
this may partially account for the diverse miRNA identified.
Importantly, these studies highlight the importance and poten-
tial application of circulating miRNA as biomarkers that can
discriminate non-metastatic from metastatic breast cancer.
Additionally, miRNAs have been identified in metastatic
breast cancer tissue samples [9–11, 48, 112–114]. While there
is some correlation between circulating and tissue
microRNAs, again a large diversity of miRNAs were identi-
fied. The number of individual non-overlapping miRNAs
identified highlights the complexity of metastasis, staging
and breast cancer subtype definition. This emphasizes the
need for further comprehensive investigations using similar
comparable experimental methodology with more defined/
improved breast cancer typing criteria.
4 Circulating miRNA in other metastatic tumours
While the identification of circulating miRNA in breast cancer
is progressing rapidly, exploring miRNAs investigated in
other (often related) metastatic cancers may inform current
work in the breast cancer field. Significantly, many of the
circulating miRNA observed in other metastatic diseases have
likewise been observed in metastatic breast cancer studies.
4.1 miRNA in metastatic colon cancer
In metastatic colon cancer, a significant increase in
miR-29a in early liver metastasis was found [117]. In
addition, high serum levels of miR-200b showed signif-
icant correlation with lymph node and distal metastatic
disease in colorectal cancers [118]. Interestingly, miR-
200b was identified as an independent predictor of tu-
mour reoccurrence in colon cancer.
Furthermore, tumour reoccurrence in colon cancer was
found to be predicted by a panel of six miRNAs (miR-15a,
miR-103, miR-148a, miR-320a, miR-451 and miR-596)
[115]. Recently in metastatic colon cancer, three miRNAs
(miR-106a, miR-130b and miR-484) were found to be signif-
icantly overexpressed in patients not responding to first-line
chemotherapy [116].
4.2 miRNA in metastatic cervical cancer
In cervical squamous cell carcinoma, a group of six miRNAs
(miR-20a, miR-1246, miR-2392, miR-3147, miR-3162-5p,
miR-4484) were found to identify lymph node metastasis
[124]. Supporting this, miR-20a was found to be significantly
increased in patients with lymph node positive cervical cancer,
compared to both controls and patients with lymph node neg-
ative disease [122].
4.3 miRNA in metastatic gastric cancer
A recent study identified six miRNAs significantly increased
in lymph nodemetastases of gastric cancer: miR-21, miR-27a,
miR-106b, miR-146a, miR-148a and miR-223 [123]. In
Table 4 Metastatic breast cancer treatment regimes by subtype
Subtype Circulating miRNA Menopause Node negative Node positive
Luminal A miR-19a, miR-205 Pre Tamoxifen±chemotherapy Chemotherapy+tamoxifen±ovarian ablation
Post Aromatase inhibitor (AI)+tamoxifen±chemotherapy Chemotherapy+AI with tamoxifen
Luminal B N.D Pre Tamoxifen+Herceptin±chemotherapy Chemotherapy+Herceptin+tamoxifen
Post AI with tamoxifen+herceptin±
chemotherapy
Chemotherapy+herceptin+AI with tamoxifen






Bone disease adds denosumab, zoledronic acid or pamidronate to chemotherapy regime
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addition, a significant increase in levels of miR-21, miR-146a
and miR-148a were found to correlate with increased spread
in the lymph node.
4.4 miRNA in metastatic prostate cancer
Recent work in metastatic prostate cancer found miR-
141 to accurately predict treatment response, compared
to standard markers such as prostate-specific antigen
(PSA), lactate dehydrogenase and circulating tumour
cells [119]. Interestingly, levels of miRA-141 were
found to be elevated in bone metastatic prostate cancer
[120]. Importantly, miR-141 expression levels were
found to correlate to alkaline phosphatase but not to
PSA. A further study looking at metastatic castration
resistant prostate cancer again found miR-141, plus
miR-375 and miR-378 to be overexpressed compared
to low-risk localized patients [121].
Table 5 MicroRNA in metastatic
tumours MicroRNA Tumour Ref. Cohort (N)
miRNA-105 Breast (serum) [102] 38 Patients
miRNA-21 Breast (serum) [103] 102 Patients, 20
controls
miRNA-141, miRNA-200a, miRNA-200b, miRNA-200c,
miRNA-203, miRNA-210, miRNA-375, miRNA-801
Breast (serum) [104] 61 Patients, 76
controls
miRNA-215, miRNA-299-5p, miRNA-411, miRNA-452 Breast (serum) [105] 75 Patients, 20
controls
miRNA-20a, miRNA-214 Breast (serum) [106] 48 Patients, 54
controls
miRNA-210 Breast (serum) [94] 8 Patients, 31
controls
miRNA-17, miRNA-155 Breast (serum) [107] 72 Patients, 40
controls
miRNA-10b, miRNA-373 Breast (serum) [108] 35 Patients, 10
controls
miRNA-10b, miRNA-34a, miRNA-155 Breast (serum) [7] 30 Patients, 29
controls
miRNA-10b Breast (serum) [109] 20 Patients, 10
controls
miRNA-10b Breast (serum) [110] 122 Patients, 59
controls
miRNA-10b Breast (serum) [111] 23 Patients
miRNA-126, miRNA-335 Breast (tissue) [48] 11 Patients
miRNA-21, miRNA-139-5p, miRNA-486-5p Breast (tissue) [9] 6 Patients
Let 7i, miRNA-16, miRNA-26a, miRNA-27a, miRNA-143,
miRNA-196a, miRNA-375, miRNA-503, miRNA-519a,
miRNA-519b-3q, miRNA-361-5p
Breast (tissue) [10] 48 Patients
miRNA-27b-3q, miRNA-107, miRNA-103a-3p Breast (tissue) [11] 58 Patients
miRNA-22 Breast (tissue) [112] 108 Patients
miRNA-373 Breast (tissue) [113] 11 Patients
miRNA-21 Breast (tissue) [114] 113 Patients
miRNA-15a, miRNA-103, miRNA-148a, miRNA-320a,
miRNA-451, miRNA-596
Colon (serum) [115] 30 Patients
miRNA-27b, miRNA-158a, miRNA-326 Colon (serum) [116] 150 Patients
miRNA-29a Colon (serum) [117] 20 Patients
miRNA-200c Colon (serum) [118] 182 Patients
miRNA-141 Prostate (serum) [119] 21 Patients
miRNA-141 Prostate (serum) [120] 56 Patients
miRNA-141, miRNA-375, miRNA-378 Prostate (serum) [121] 84 Patients
miRNA-20a, miRNA-203 Cervical (serum) [122] 80 Patients
miRNA-21, miRNA-27a, miRNA-106b, miRNA-146a,
miRNA-148a, miRNA-223
Gastric (serum) [123] 20 Controls, 16
patients
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5 Conclusions
Our understanding of metastatic breast cancer has advanced
considerably over the last number of years, yet metastasis
remains the major cause of morbidity and mortality in breast
cancer. Up to one in three breast cancer patients diagnosed
will develop metastatic breast cancer, and despite current
treatments, 78% of these will die within 5 years. Clearly, there
is an urgent need to find new clinically relevant biomarkers
and tests to allow the early detection of metastatic breast can-
cer and for the monitoring of treatment response.
The defining of different molecular breast cancer subtypes
has significantly aided the treatment of breast cancer, allowing
more tailored individual treatment regimes. Significantly,
treatment using hormone therapies and Herceptin has in-
creased survival in luminal and HER2 positive breast cancers.
However, basal (triple negative) breast cancers continue to
have poorer outcomes. Chemotherapy remains the major
treatment for metastatic breast cancer, yet similar regimes
are given for all subtypes. Additional research is needed to
define further subtypes and identify new markers that predict
their response to chemotherapy. MicroRNAs have emerged as
one such potential marker for predicting metastatic disease
and response to treatment. Recently, a small number of
miRNAs have shown increased expression in the circulation
of metastatic breast cancer patients. In particular, miR-10b has
been highlighted across five studies and has been linked to
specific sites of distal metastasis. Despite the differences in the
rate of metastasis across the breast cancer subtypes, to our
knowledge, only one study (Dai et al.) has assessed the
miRNA profiles associated with each molecular subtype
[125]. Importantly, this study used tumour samples, not circu-
lating miRNA, and did not include metastatic disease. A study
investigating circulating miRNA profiles in patients with dif-
ferent molecular subtypes and metastatic disease is greatly
needed. Furthermore, the use of different extraction methods
and starting material may explain the lack of consensus be-
tween microRNAs currently identified in the indicated stud-
ies. However, another possible reason may be the diversity of
sites of distal metastasis in each study. Only two studies have
explored metastatic site-specific miRNAs, Ahmad et al. [109]
(brain) and Zhao et al. [110] (bone), with both studies identi-
fying elevated miR-10b. The identification of truly site- or
subtype-specific metastatic miRNA may provide the diagnos-
tic tool required to improve personalized metastatic breast
cancer treatments. Interestingly, many circulating miRNAs
identified in metastatic breast cancer were also found in stud-
ies of other metastatic cancers. This may indicate that the
identified miRNAs are indicative of the sites of metastasis or
that the miRNAs correspond to common underlying mecha-
nisms of cancer metastasis.
Here, we highlighted the current knowledge and potential
of microRNAs as biomarkers for improving the diagnosis and
treatment of metastatic breast cancer. However, significant
further directed research is needed to identify and confirm
miRNA that can predict site-specific metastasis disease out-
come or patient response to treatments.
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